Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination.

Lee JY, Kim MJ, Thomas S, Oorschot V, Ramm G, Aui PM, Sekine Y, Deliyanti D, Wilkinson-Berka J, Niego B, Harvey AR, Theotokis P, McLean C, Strittmatter SM, Petratos S.

J Neurosci. 2019 Jul 10;39(28):5562-5580. doi: 10.1523/JNEUROSCI.1760-18.2019. Epub 2019 May 6.

PMID:
31061088
2.

Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats.

Alrashdi SF, Deliyanti D, Wilkinson-Berka JL.

Exp Eye Res. 2018 Nov;176:1-9. doi: 10.1016/j.exer.2018.06.025. Epub 2018 Jun 23.

PMID:
29944850
3.

Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy.

Deliyanti D, Alrashdi SF, Tan SM, Meyer C, Ward KW, de Haan JB, Wilkinson-Berka JL.

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):815-825. doi: 10.1167/iovs.17-22920.

PMID:
29411009
4.

Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells.

Appukuttan B, Ma Y, Stempel A, Ashander LM, Deliyanti D, Wilkinson-Berka JL, Smith JR.

Clin Exp Ophthalmol. 2018 Aug;46(6):652-660. doi: 10.1111/ceo.13155. Epub 2018 Feb 23.

PMID:
29360265
5.

Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1).

Li J, Huynh P, Dai A, Wu T, Tu Y, Chow B, Kiriazis H, Du XJ, Bach LA, Wilkinson-Berka JL, Biros E, Walker P, Nataatmadja M, West M, Golledge J, Allen TJ, Cooper ME, Chai Z.

Diabetes. 2018 Apr;67(4):755-768. doi: 10.2337/db17-0134. Epub 2018 Jan 8.

6.

Endothelin-2 Injures the Blood-Retinal Barrier and Macroglial Müller Cells: Interactions with Angiotensin II, Aldosterone, and NADPH Oxidase.

Alrashdi SF, Deliyanti D, Talia DM, Wilkinson-Berka JL.

Am J Pathol. 2018 Mar;188(3):805-817. doi: 10.1016/j.ajpath.2017.11.009. Epub 2017 Dec 15.

PMID:
29248456
7.

Oxidative stress and reactive oxygen species: a review of their role in ocular disease.

Ung L, Pattamatta U, Carnt N, Wilkinson-Berka JL, Liew G, White AJR.

Clin Sci (Lond). 2017 Dec 4;131(24):2865-2883. doi: 10.1042/CS20171246. Print 2017 Dec 15. Review.

PMID:
29203723
8.

Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination.

Lee JY, Kim MJ, Deliyanti D, Azari MF, Rossello F, Costin A, Ramm G, Stanley EG, Elefanty AG, Wilkinson-Berka JL, Petratos S.

EBioMedicine. 2017 Nov;25:122-135. doi: 10.1016/j.ebiom.2017.10.016. Epub 2017 Oct 19.

9.

Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis.

Deliyanti D, Talia DM, Zhu T, Maxwell MJ, Agrotis A, Jerome JR, Hargreaves EM, Gerondakis S, Hibbs ML, Mackay F, Wilkinson-Berka JL.

Nat Commun. 2017 Sep 29;8(1):748. doi: 10.1038/s41467-017-00751-w.

10.

The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies.

Wilkinson-Berka JL, Deliyanti D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S41. No abstract available.

11.

Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis.

Wang B, Yao K, Huuskes BM, Shen HH, Zhuang J, Godson C, Brennan EP, Wilkinson-Berka JL, Wise AF, Ricardo SD.

Mol Ther. 2016 Aug;24(7):1290-301. doi: 10.1038/mt.2016.90. Epub 2016 May 18.

12.

Inhibition of the Nuclear Receptor RORγ and Interleukin-17A Suppresses Neovascular Retinopathy: Involvement of Immunocompetent Microglia.

Talia DM, Deliyanti D, Agrotis A, Wilkinson-Berka JL.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1186-96. doi: 10.1161/ATVBAHA.115.307080. Epub 2016 Apr 7.

PMID:
27055905
13.

A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.

Deliyanti D, Lee JY, Petratos S, Meyer CJ, Ward KW, Wilkinson-Berka JL, de Haan JB.

Clin Sci (Lond). 2016 Aug 1;130(15):1375-87. doi: 10.1042/CS20160068. Epub 2016 Mar 22.

PMID:
27005782
14.

VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury.

Sato T, Paquet-Fifield S, Harris NC, Roufail S, Turner DJ, Yuan Y, Zhang YF, Fox SB, Hibbs ML, Wilkinson-Berka JL, Williams RA, Stacker SA, Sly PD, Achen MG.

J Pathol. 2016 Jun;239(2):152-61. doi: 10.1002/path.4708. Epub 2016 Mar 30.

15.

FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy.

Deliyanti D, Zhang Y, Khong F, Berka DR, Stapleton DI, Kelly DJ, Wilkinson-Berka JL.

PLoS One. 2015 Jul 29;10(7):e0134392. doi: 10.1371/journal.pone.0134392. eCollection 2015.

16.

Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina.

Deliyanti D, Wilkinson-Berka JL.

J Neuroinflammation. 2015 Jul 30;12:136. doi: 10.1186/s12974-015-0363-z.

17.

Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.

Figgett WA, Deliyanti D, Fairfax KA, Quah PS, Wilkinson-Berka JL, Mackay F.

J Autoimmun. 2015 Jul;61:9-16. doi: 10.1016/j.jaut.2015.04.007. Epub 2015 May 29.

PMID:
26027434
18.

Are reactive oxygen species still the basis for diabetic complications?

Di Marco E, Jha JC, Sharma A, Wilkinson-Berka JL, Jandeleit-Dahm KA, de Haan JB.

Clin Sci (Lond). 2015 Jul;129(2):199-216. doi: 10.1042/CS20150093. Review.

PMID:
25927680
19.

Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Müller cell and vascular injury in the retina.

Tan SM, Deliyanti D, Figgett WA, Talia DM, de Haan JB, Wilkinson-Berka JL.

Exp Eye Res. 2015 Jul;136:1-8. doi: 10.1016/j.exer.2015.04.015. Epub 2015 Apr 24.

PMID:
25912997
20.

Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia.

Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ, Wilkinson-Berka JL.

Clin Exp Pharmacol Physiol. 2015 May;42(5):537-48. doi: 10.1111/1440-1681.12376.

PMID:
25707593
21.

Retinal vasculopathy is reduced by dietary salt restriction: involvement of Glia, ENaCα, and the renin-angiotensin-aldosterone system.

Deliyanti D, Armani R, Casely D, Figgett WA, Agrotis A, Wilkinson-Berka JL.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2033-41. doi: 10.1161/ATVBAHA.114.303792. Epub 2014 Jul 10.

PMID:
25012132
22.

The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity.

Hatzopoulos KM, Vessey KA, Wilkinson-Berka JL, Fletcher EL.

Invest Ophthalmol Vis Sci. 2014 Jun 3;55(6):3957-70. doi: 10.1167/iovs.13-13532.

PMID:
24894399
23.

NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy.

Wilkinson-Berka JL, Deliyanti D, Rana I, Miller AG, Agrotis A, Armani R, Szyndralewiez C, Wingler K, Touyz RM, Cooper ME, Jandeleit-Dahm KA, Schmidt HH.

Antioxid Redox Signal. 2014 Jun 10;20(17):2726-40. doi: 10.1089/ars.2013.5357. Epub 2013 Oct 30.

24.

Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system.

McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL.

Clin Exp Pharmacol Physiol. 2013 Aug;40(8):571-9. doi: 10.1111/1440-1681.12099. Review.

PMID:
23601050
25.

Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy.

Wilkinson-Berka JL, Rana I, Armani R, Agrotis A.

Clin Sci (Lond). 2013 May;124(10):597-615. doi: 10.1042/CS20120212. Review.

PMID:
23379642
26.

Lack of the antioxidant glutathione peroxidase-1 (GPx1) exacerbates retinopathy of prematurity in mice.

Tan SM, Stefanovic N, Tan G, Wilkinson-Berka JL, de Haan JB.

Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):555-62. doi: 10.1167/iovs.12-10685.

PMID:
23287791
27.

The renin-angiotensin system and advanced glycation end-products in diabetic retinopathy: impacts and synergies.

Miller AG, Zhu T, Wilkinson-Berka JL.

Curr Clin Pharmacol. 2013 Nov;8(4):285-96. Review.

PMID:
23173957
28.

Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies.

Sedeek M, Montezano AC, Hebert RL, Gray SP, Di Marco E, Jha JC, Cooper ME, Jandeleit-Dahm K, Schiffrin EL, Wilkinson-Berka JL, Touyz RM.

J Cardiovasc Transl Res. 2012 Aug;5(4):509-18. doi: 10.1007/s12265-012-9387-2. Epub 2012 Jun 19. Review.

PMID:
22711281
29.

The retinal renin-angiotensin system: roles of angiotensin II and aldosterone.

Wilkinson-Berka JL, Agrotis A, Deliyanti D.

Peptides. 2012 Jul;36(1):142-50. doi: 10.1016/j.peptides.2012.04.008. Epub 2012 Apr 17. Review.

PMID:
22537944
30.

Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy.

Deliyanti D, Miller AG, Tan G, Binger KJ, Samson AL, Wilkinson-Berka JL.

Hypertension. 2012 Mar;59(3):607-13. doi: 10.1161/HYPERTENSIONAHA.111.188136. Epub 2012 Jan 23.

PMID:
22275532
31.

Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat.

Wilkinson-Berka JL, Tan G, Binger KJ, Sutton L, McMaster K, Deliyanti D, Perera G, Campbell DJ, Miller AG.

Diabetologia. 2011 Oct;54(10):2724-35. doi: 10.1007/s00125-011-2239-9. Epub 2011 Jul 14.

PMID:
21755314
32.

Characterization of retinal function and glial cell response in a mouse model of oxygen-induced retinopathy.

Vessey KA, Wilkinson-Berka JL, Fletcher EL.

J Comp Neurol. 2011 Feb 15;519(3):506-27. doi: 10.1002/cne.22530.

PMID:
21192081
33.

Prorenin and the (pro)renin receptor: recent advances and implications for retinal development and disease.

Wilkinson-Berka JL, Miller AG, Binger KJ.

Curr Opin Nephrol Hypertens. 2011 Jan;20(1):69-76. doi: 10.1097/MNH.0b013e328341328a. Review.

PMID:
21099684
34.

Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.

Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, Cooper ME, Wilkinson-Berka JL.

Diabetes. 2010 Dec;59(12):3208-15. doi: 10.2337/db10-0552. Epub 2010 Sep 17.

35.

Prorenin and the (pro)renin receptor: do they have a pathogenic role in the retina?

Wilkinson-Berka JL, Miller AG, Fletcher EL.

Front Biosci (Elite Ed). 2010 Jun 1;2:1054-64. Review.

PMID:
20515775
36.

The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature.

Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL.

Prog Retin Eye Res. 2010 Jul;29(4):284-311. doi: 10.1016/j.preteyeres.2010.03.003. Epub 2010 Apr 7.

PMID:
20380890
37.

RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina.

Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG.

Hypertension. 2010 Jun;55(6):1454-60. doi: 10.1161/HYPERTENSIONAHA.109.148221. Epub 2010 Apr 5.

PMID:
20368504
38.

Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity.

Downie LE, Hatzopoulos KM, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Kalloniatis M, Fletcher EL.

J Comp Neurol. 2010 Jan 1;518(1):41-63. doi: 10.1002/cne.22205.

PMID:
19882719
39.

The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy.

Fletcher EL, Downie LE, Hatzopoulos K, Vessey KA, Ward MM, Chow CL, Pianta MJ, Vingrys AJ, Kalloniatis M, Wilkinson-Berka JL.

Doc Ophthalmol. 2010 Feb;120(1):67-86. doi: 10.1007/s10633-009-9193-6. Epub 2009 Sep 8. Review.

PMID:
19763649
40.

(Pro)renin receptor: a treatment target for diabetic retinopathy?

Wilkinson-Berka JL, Campbell DJ.

Diabetes. 2009 Jul;58(7):1485-7. doi: 10.2337/db09-0604. No abstract available.

41.

Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina.

Downie LE, Vessey K, Miller A, Ward MM, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL.

Neuroscience. 2009 Jun 16;161(1):195-213. doi: 10.1016/j.neuroscience.2009.02.084. Epub 2009 Mar 17.

PMID:
19298848
42.

Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.

Wilkinson-Berka JL, Tan G, Jaworski K, Harbig J, Miller AG.

Circ Res. 2009 Jan 2;104(1):124-33. doi: 10.1161/CIRCRESAHA.108.176008. Epub 2008 Nov 26. Erratum in: Circ Res. 2017 Apr 14;120(8):e31.

PMID:
19038868
43.

Prorenin and the (pro)renin receptor in ocular pathology.

Wilkinson-Berka JL.

Am J Pathol. 2008 Dec;173(6):1591-4. doi: 10.2353/ajpath.2008.080757. Epub 2008 Oct 30. Review. No abstract available.

44.

AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy.

Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL.

Glia. 2008 Aug 1;56(10):1076-90. doi: 10.1002/glia.20680.

PMID:
18442090
45.

Update on the treatment of diabetic retinopathy.

Wilkinson-Berka JL, Miller AG.

ScientificWorldJournal. 2008 Feb 6;8:98-120. doi: 10.1100/tsw.2008.25. Review.

46.

Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats.

Jayasooriya AP, Begg DP, Chen N, Mathai ML, Sinclair AJ, Wilkinson-Berka J, Wark JD, Weisinger HS, Weisinger RS.

Prostaglandins Leukot Essent Fatty Acids. 2008 Jan;78(1):67-72.

PMID:
18083506
47.

Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy.

Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL.

Curr Pharm Des. 2007;13(26):2699-712. Review.

PMID:
17897014
48.

An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy.

Wilkinson-Berka JL, Lofthouse S, Jaworski K, Ninkovic S, Tachas G, Wraight CJ.

Mol Vis. 2007 Aug 29;13:1529-38.

PMID:
17893652
49.

Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity.

Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL.

J Comp Neurol. 2007 Oct 1;504(4):404-17.

PMID:
17663451
50.

Progressive diabetic nephropathy in the Ren-2 rat.

Kelly DJ, Wilkinson-Berka JL, Gilbert RE.

Am J Physiol Renal Physiol. 2007 May;292(5):F1662; author reply F1663. No abstract available.

Supplemental Content

Loading ...
Support Center